IGF1 and Alzheimer disease: Since IGF-1 or IGF-2 suppression of GSK-3β activity [69] reduces the neurotoxic effects of AβPP [70-73], the neuro-protective properties of these and related trophic factors could be exploited for therapeutic purposes in AD.